drug · small molecule
suzetrigine
Marketedupdated 3mo agoby $VERX Vertex, Inc.🔗 ChEMBL
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 4Small molecule drug with a maximum clinical stage of Approval (across all indications), with 2 investigational indications.
all catalysts(2)
Trials studying suzetrigine
- phase1Effects of Efavirenz on the Pharmacokinetics of Suzetrigine in Healthy Participants
- phase3Assessing Suzetrigine for Pain Reduction Following Ureteroscopic Surgery
- phase3Evaluation of Efficacy and Safety of Suzetrigine (SUZ) for Pain Associated With Diabetic Peripheral Neuropathy
- phase4Evaluation of Pain Treatment After Total Knee Arthroplasty
- phase3Evaluation of Efficacy and Safety of Suzetrigine for Pain Associated With Diabetic Peripheral Neuropathy
- phase4Suzetrigine for Non-Mastectomy Breast Surgery
- phase1Evaluation of the Excretion of Suzetrigine Into Breast Milk in Healthy Lactating Female Participants
- phase3Evaluation of the Long-term Safety and Effectiveness of Suzetrigine (SUZ) in Participants With Painful Diabetic Peripheral Neuropathy (DPN)
Patent cliff
source: FDA Orange Bookfirst barrier falls
Jan 30, 2030
~3.4 years out
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (1)
- Dec 4, 2040compositionUS 11834441
FDA exclusivities (1)
- Jan 30, 2030NCENew Chemical Entity (5y)3.4y
News(10)
- Trump's FDA pick Overton good for psychedelics, new pain meds but bad for vaccines: analystsIf confirmed by the Senate, Heidi Overton—officially revealed Wednesday as President Donald Trump’s choice for FDA commissioner—is expected to be a boon for developers of psychedelic therapeutics a…biospace · 7h ago
- Lilly pens $370M deal with OmniAb for ion channel collab, but details remain vagueAntibody platform business OmniAb continues to rack up Big Pharma partnerships, with Eli Lilly signing off on up to $370 million biobucks tied to an ion channel program.fiercebiotech · 2d ago
- BlossomHill, Latigo bloom on Nasdaq with oversubscribed IPOsBlossomHill Therapeutics will use its $150 million IPO proceeds to power the Phase 1/2 development of a non-small cell lung cancer drug, while Latigo Therapeutics will bring in more than $345 milli…biospace · 9d ago
- Latigo IPO raises nearly $350M for pain drug developmentThe company could rival Vertex and Lilly in the burgeoning market for non-opioid, ion-channel-blocking pain drugs. Its offering also adds to a recent and significant uptick in large biotech IPOs.biopharma_dive · 12d ago
- BlossomHill, Latigo outshine IPO expectations with oversubscribed debutsTwo growing biotechs blasted through their IPO expectations Friday, with Blossom Hill Therapeutics and Latigo Biotherapeutics each raising at least 30% more than expected in their stock market debuts.fiercebiotech · 12d ago
- Latigo laces up for $247M IPO to fund non-opioid pain drug rival to Vertex’s JournavxLatigo Biotherapeutics has fleshed out its plans for an IPO to finance the development of its clinical-stage pipeline of non-opioid pain management drugs.fiercebiotech · 15d ago
- STAT+: Eli Lilly to allow more patients to apply for special access to unapproved obesity drugDoctors are asking how to get retatrutide for their patients, after Eli Lilly gave one man early access.stat · 16d ago
- STAT+: Is there a pharma mega-merger in the making?Moderna's imminent FDA vaccine decision, TCGX launches $400M Asia biotech fund, and more biotech newsstat · 16d ago
- STAT+: BioNTech names Guido Oelkers its new CEOGuido Oelkers will take over as the new CEO of BioNTech, replacing company cofounder Ugur Sahin.stat · 16d ago
- Opinion: Limb girdle muscular dystrophy patients face a maddening reality“Too often, regulatory tools authorized to speed patient access to breakthrough treatments are being used in ways that even prevent approval,” writes Kat Bryant Knudson.stat · 19d ago
Data sources
last refreshed 1h ago
Found something off?
comments(0)
5-min edit window · permanent after that